文献速递淋巴瘤

依维莫司联合地塞米松、大剂量阿糖胞苷和顺铂再诱导治疗复发或难治性经典型霍奇金淋巴瘤:德国霍奇金研究组的一项实验性I/II期多中心试验(GHSG HD-R3i)

Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).
PubMed 文献 · Br J Haematol · 2021-11-14

该实验性I/II期多中心试验纳入50例18-60岁适合移植的复发/难治性经典型霍奇金淋巴瘤患者,在DHAP方案基础上加用依维莫司(10 mg/天,第0-13天)组成everDHAP再诱导方案。两周期后基于CT的完全缓解率为27%(12/45),未达到预设的≥40%主要终点,依维莫司联合DHAP可行但未能提高疗效。

要点

  • everDHAP两周期后基于CT的完全缓解率为27%(12/45),未达≥40%的主要终点。
  • 依维莫司联合DHAP方案可行,但未能显示疗效改善。
  • 因招募不佳,随机对照安慰剂组在入组9例后于2015年10月停止。

核心结论

  • 在DHAP方案中加入依维莫司可行,但everDHAP方案未能显示疗效改善,试验未达到主要终点。

研究设计与样本

  • 实验性I/II期多中心试验,纳入50例18-60岁组织学确诊的复发/难治性经典型霍奇金淋巴瘤且适合移植的患者进入II期everDHAP组。
  • 依维莫司剂量为10 mg/天(由I期部分确定),于每个DHAP周期的第0-13天给药。
  • 主要终点为两周期everDHAP后基于CT的完全缓解率,预期≥40%。

主要发现

  • II期everDHAP组50例中2例不可评估,3例因毒性终止。
  • 两周期everDHAP后基于CT的完全缓解率为27%(n=12/45),未达到主要终点。
  • 随机对照安慰剂组在入组9例后因招募不佳于2015年10月停止。

关键数值与推荐

  • 主要终点为两周期everDHAP后基于CT的完全缓解率,预期≥40%,实际为27%(n=12/45)。

局限性

  • 随机对照安慰剂组因招募不佳在入组9例后于2015年10月停止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reinduction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (HDCT + ASCT) is second-line standard of care for transplant-eligible patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) but has a high failure rate. Because response to reinduction is predictive of the outcome after HDCT + ASCT, we aimed to improve the standard dexamethasone, high-dose cytarabine and cisplatinum (DHAP) reinduction regimen by addition of the oral mammalian target of rapamycin inhibitor everolimus (everDHAP). Transplant-eligible patients aged 18-60 years with histologically confirmed r/r cHL were included in this experimental phase I/II trial. Everolimus (10 mg/day, determined in phase-I-part) was administered on day 0-13 of each DHAP cycle. From July 2014 to March 2018, 50 patients were recruited to the phase II everDHAP group; two were not evaluable, three discontinued due to toxicity. Randomization to a placebo group stopped in October 2015 due to poor recruitment after nine patients. The primary end-point of computed tomography (CT)-based complete remission (CR) after two cycles of everDHAP was expected to be ≥40%. With a CT-based CR rate of 27% (n = 12/45) after two cycles of everDHAP the trial did not meet the primary end-point. Adding everolimus to DHAP is thus feasible; however, the everDHAP regimen failed to show an improved efficacy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gillessen S, Hüttmann A, Vucinic V, et al. Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i). Br J Haematol. 2021. PMID: 34775591. doi:10.1111/bjh.17878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。